Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ETTX =MC $84 M/ Cash $63 M / 2 BIG Phase 3 Programs

17 Jun 2020 06:44 AM <--

16 Jun 2020 02:55 PM

Return to ETTX =MC $84 M/ Cash $63 M / 2 BIG Phase 3 Programs

(ETTX-DD) Low Valuation of $84 Million / STRONG Cash of $63 Million/ 2 attractive Drugs in late Phase 3 with LARGE market potential with first readout within 6-7 months / Insider & Institutional investors holding most of the shares /Low float stock = $15-20 stock here on this undiscovered biotech gem .GL

Entasis Therapeutics (ETTX)

Market Cap: $84 million
Cash: 63 Million
Price $3.05

Shares Out: 28 million

Presentation June
investors.entasistx.com

Major Shareholders

Innoviva Inc...14M
Novo Holdings A/S...2.2M
AstraZeneca PLC...2.2M
Clarus Ventures, LLC...1.6M
Pivotal ...1.2M
Sofinnova ...1.2M
Frazier ...1.0M
TPG Capital, L.P...1.0M
Eventide Asset ...879.5K

Granahan ...154.7K